Markets:

Overview

News

Currencies

International

Treasuries

MacroGenics, Inc. - Common Stock (NQ:MGNX)

4.179 -0.141 (-3.26%)

Streaming Delayed Price Updated: 10:21 AM EDT, Sep 9, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about MacroGenics, Inc. - Common Stock

< Previous 1 2

...

6 7 8 9 10 11 12 13 Next >

MacroGenics (MGNX) Q3 2021 Earnings Call Transcript ↗

November 03, 2021

MGNX earnings call for the period ending September 30, 2021.

Via The Motley Fool

Topics Earnings

The Daily Biotech Pulse: Pfizer Reports Solid Q3 Earnings, Regulatory Setback For Legend, Lilly to Supply Additional COVID-19 Antibody Cocktails To US ↗

November 02, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus SAB Spikes On Analyst Action SAB Biotherapeutics, Inc. (NASDAQ: SABS) shares...

Via Benzinga

Earnings Scheduled For November 2, 2021 ↗

November 02, 2021

Companies Reporting Before The Bell • Thomson Reuters (NYSE:TRI) is expected to report quarterly earnings at $0.48 per share on revenue of $1.86 billion. •...

Via Benzinga

Week In Review: MicroTech Medical Staging $245 Million HK IPO For Diabetes Products ↗

October 10, 2021

MicroTech Medical, a Hangzhou company that offers diabetes monitoring and treatment devices, is conducting a Hong Kong IPO that would raise $254 million at the top of the price range. LianBio has filed...

Via Talk Markets

Topics Initial Public Offering

The Week Ahead In Biotech (Oct. 31-Nov. 6): Earnings Pick Up Pace, Eton Awaits Seizure Drug Approval, Kidney Conference, More IPOs In The Pipeline ↗

October 31, 2021

Biotech stocks rose a third week running in the week ending Oct. 29 amid positive reaction to earnings. Big pharma earnings were mostly better than expected. Merck & Co, Inc...

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For October 19, 2021 ↗

October 19, 2021

Upgrades Maxim Group upgraded the previous rating for Indaptus Therapeutics Inc (NASDAQ:

Via Benzinga

Last Week's Notable Insider Buys Included Evergy, Frontier Communications And More ↗

October 02, 2021

Insider buying can be an encouraging signal for potential investors, especially when markets are uncertain. The week's most notable insider buys were at an REIT, a...

Via Benzinga

3 Stocks Insiders Are Buying ↗

October 01, 2021

When insiders purchase shares, it indicates their confidence in the company's prospects or that they view the stock as a bargain. Either way, this signals an opportunity to go...

Via Benzinga

Why Are I-Mab Shares Trading Higher On Tuesday? ↗

September 28, 2021

The Center for Drug Evaluation of China National Medical Products Administration has signed off I-Mab's (NASDAQ: IMAB) IND application to initiate a Phase 2...

Via Benzinga

Notable Insider Buys Of The Past Week Include Designer Brands, MacroGenics And More ↗

September 25, 2021

Insider buying can be an encouraging signal for potential investors, especially when markets are near all-time highs. The week's most notable insider buys were at two...

Via Benzinga

56 Biggest Movers From Yesterday ↗

September 17, 2021

Check out these big penny stock gainers and losers Losers Vera Therapeutics, Inc. (NASDAQ: VERA) shares tumbled 26.5% to settle at $22.48. MacroGenics, Inc. (NASDAQ...

Via Benzinga

Mid-Afternoon Market Update: Dow Falls 70 Points; Aerie Pharmaceuticals Shares Plunge ↗

September 16, 2021

Toward the end of trading Thursday, the Dow traded down 0.20% to 34,745 while the NASDAQ fell 0.03% to 15,157.61. The S&P also fell, dropping 0.21% to 4,471.34. The U.S. has...

Via Benzinga

Topics Stocks

MacroGenics Shares Fall After MGC018 Data Fails To Impress At ESMO Presentation ↗

September 16, 2021

MacroGenics Inc (NASDAQ: MGNX) announced preliminary safety and anti-tumor activity data from dose-expansion cohorts of the Phase 1 trial of MGC018. The data was...

Via Benzinga

12 Health Care Stocks Moving In Thursday's Intraday Session ↗

September 16, 2021

Gainers Leap Therapeutics (NASDAQ:LPTX) stock moved upwards by 27.72% to $2.46 during Thursday's regular session. As of 12:30 EST, this security is trading at a volume...

Via Benzinga

Mid-Day Market Update: Gold Drops Over 2%; Leap Therapeutics Shares Jump ↗

September 16, 2021

Midway through trading Thursday, the Dow traded down 0.74% to 34,557.75 while the NASDAQ fell 0.67% to 15,060.25. The S&P also fell, dropping 0.79% to 4,445.34. The U.S. has...

Via Benzinga

Topics Stocks

Why MacroGenics Stock Is Tanking Today ↗

September 16, 2021

Investors weren't thrilled with the company's latest clinical data.

Via The Motley Fool

38 Stocks Moving In Thursday's Mid-Day Session ↗

September 16, 2021

Gainers IronNet Cybersecurity, Inc. (NASDAQ: IRNT) shares jumped 30.4% to $41.90 amid increased retail investor interest in the stock on social media. Dutch Bros Inc. (NYSE: BROS...

Via Benzinga

Mid-Morning Market Update: Markets Down; US Retail Sales Unexpectedly Increase in August ↗

September 16, 2021

Following the market opening Thursday, the Dow traded down 0.45% to 34,657.69 while the NASDAQ fell 0.66% to 15,061.97. The S&P also fell, dropping 0.62% to 4,453.04. The U.S...

Via Benzinga

Topics Stocks

12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗

September 16, 2021

Gainers Leap Therapeutics (NASDAQ:LPTX) stock rose 32.64% to $2.56 during Thursday's pre-market session. The company's market cap stands at $152.7 million. Phio...

Via Benzinga

The Week Ahead In Biotech (Sept. 12-18): Calliditas FDA Decision, Adcom Review For Pfizer/BioNTech COVID-19 Vaccine, Oncology Conference And IPOs ↗

September 12, 2021

Biotech stocks retreated in the holiday-shortened week ending Sept. 10, reversing course from the previous week. Humanigen, Inc. (NASDAQ: HGEN) was among the biggest...

Via Benzinga

Why MacroGenics Soared Nearly 9% Higher Today ↗

September 09, 2021

Investors are signaling hope in the company's top drug, despite a disappointing final analysis.

Via The Motley Fool

MacroGenics Stock Dives As Cancer Drug Shows Mixed Results Vs. Roche Blockbuster ↗

September 08, 2021

A fully approved breast cancer drug from MacroGenics failed to pass muster in a final analysis, and MGNX stock dipped Wednesday.

Via Investor's Business Daily

The Daily Biotech Pulse: MacroGenics' Clinical Trial Disappointment, Sanofi to Buy Kadmon, Alector Loses 2 Key Executives, ADMA's FDA Nod ↗

September 08, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 7) Adial Pharmaceuticals, Inc...

Via Benzinga

MacroGenics' Cancer Drug Margenza Flops On Overall Survival Analysis ↗

September 08, 2021

MacroGenics Inc (NASDAQ: MGNX) scored a big win with its full approval for anti-HER2 drug Margenza in December 2020 based on a head-to-head matchup with breast...

Via Benzinga

12 Health Care Stocks Moving In Monday's After-Market Session ↗

August 23, 2021

Gainers Cara Therapeutics (NASDAQ:CARA) ...

Via Benzinga

Looking into Macrogenics's Return on Capital Employed ↗

August 06, 2021

After pulling data from Benzinga Pro it seems like during Q2, Macrogenics's (NASDAQ:MGNX) reported sales totaled $30.76 million. Despite a 21.47% in earnings, the company posted a...

Via Benzinga

MacroGenics (MGNX) Q2 2021 Earnings Call Transcript ↗

July 30, 2021

MGNX earnings call for the period ending June 30, 2021.

Via The Motley Fool

Topics Earnings

Why MacroGenics Stock Is Tumbling Today ↗

July 30, 2021

The company provided its Q2 update.

Via The Motley Fool

NASDAQ:MGNX Long Term Investor Notice: Investigation of Potential Wrongdoing at MacroGenics, Inc. ↗

June 22, 2021

San Diego, CA -- (SBWIRE) -- 06/22/2021 -- Certain directors of MacroGenics, Inc. are under investigation concerning potential breaches of fiduciary duties.

Via SBWire

Topics Lawsuit

Week In Review: This Week's China Life Science Deals Total Over $2.5 Billion ↗

June 19, 2021

Shanghai's Zai Lab announced a four-drug immunonocology deal with MacroGenics worth over $1.4 billion. Shanghai's HutchMed (formerly Hutchison Chi-Med) is planning to raise $600 million in a Hong...

Via Talk Markets

< Previous 1 2

...

6 7 8 9 10 11 12 13 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.